menu
    • menu

    Company profile for Alfred E Tiefenbacher GmbH

    NEW Drugs in Dev: 2
    Default Key Product, Service and Excipients
    News
    Students Week at Tiefenbacher Group – Connecting Global Talents!

    17 Dec 2025

    // PRESS RELEASE

    Tiefenbacher Group at CPHI Frankfurt 2025

    24 Oct 2025

    // PRESS RELEASE

    Celebrating the Spirit of Diwali at Tiefenbacher Laboratories

    20 Oct 2025

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Tiefenbacher Group

    Contact Supplier

    Website

    Arvo

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    radio-compass-blog/excipient-market-overview-clariant-sets-up-its-first-peg-excipients-facility-in-us-india-harmonizes-22-excipient-monographs

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    We are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Related CompaniesRelated Companies

    About

    As a key component of the TIEFENBACHER GROUP, a 100% family-owned leader in healthcare, we offer comprehensive solutions across the entire life cycle of pharmaceutical products. Our expertise spans the development, manufacturing, and registration of generic, value-added, and innovative medicines, along with e-health solutions tailored for our B2B clients & distribution partners. Trusted globally, our outstanding capabilities in crafting top-tier dossiers and managing intricate product launches in over 80 countries. Our in-house laboratories and manufacturing facilities in India and Cyprus enable us to establish efficient supply chains.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Alfred E Tiefenbacher GmbHGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Van-der-Smissen-Strasse 1, 22767 Hamburg
    Telephone
    Telephone
    +49 404418090
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://aet.eu/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/alfred-e.-tiefenbacher-gmbh-&-co.-kg-/
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Arvo

    Arvo

    Not Confirmed

    envelop Contact Supplier

    Arvo

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/tiefenbacher-api-ingredients-gmbh-party-content-89424.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/tiefenbacher-group-party-content-21386.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    API Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/tiefenbacher-api-ingredients-gmbh-party-content-96648.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    R&D API Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/tiefenbacher-api-ingredients-gmbh-party-content-97507.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Veterinary API Product List 2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/tiefenbacher-api-ingredients-gmbh-party-content-987.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/tiefenbacher-group-party-content-26459.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Tiefenbacher Group & OnDosis Enter Strategic Partnership

    read-more

      https://www.pharmacompass.com/pdf/party/content/tiefenbacher-group-party-content-7484.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    NEWS #PharmaBuzz

    read-more
    read-more
    Students Week at Tiefenbacher Group – Connecting Global Talents!
    Students Week at Tiefenbacher Group – Connecting Global Talents!

    17 Dec 2025

    // PRESS RELEASE

    https://tiefenbacher-pharmaceuticals.com/news/students-week-at-tiefenbacher-group-connecting-global-talents/

    PRESS RELEASE
    17 Dec 2025
    Share Share
    Tiefenbacher Group at CPHI Frankfurt 2025
    Tiefenbacher Group at CPHI Frankfurt 2025

    24 Oct 2025

    // PRESS RELEASE

    https://tiefenbacher-pharmaceuticals.com/news/tiefenbacher-group-at-cphi-frankfurt-2025/

    PRESS RELEASE
    24 Oct 2025
    Share Share
    Celebrating the Spirit of Diwali at Tiefenbacher Laboratories
    Celebrating the Spirit of Diwali at Tiefenbacher Laboratories

    20 Oct 2025

    // PRESS RELEASE

    https://tiefenbacher-pharmaceuticals.com/news/celebrating-the-spirit-of-diwali-at-tiefenbacher-laboratories/

    PRESS RELEASE
    20 Oct 2025
    Share Share
    Tiefenbacher Group and Neuraxpharm announce the launch of Riulvy
    Tiefenbacher Group and Neuraxpharm announce the launch of Riulvy

    10 Oct 2025

    // PRESS RELEASE

    https://tiefenbacher-pharmaceuticals.com/news/tiefenbacher-group-and-neuraxpharm-announce-the-launch-of-riulvy-tegomil-fumarate-in-germany/

    PRESS RELEASE
    10 Oct 2025
    Share Share
    Tiefenbacher Celebrates World Science Day
    Tiefenbacher Celebrates World Science Day

    10 Sep 2025

    // PRESS REEASE

    https://tiefenbacher-pharmaceuticals.com/news/tiefenbacher-celebrates-world-science-day/

    PRESS REEASE
    10 Sep 2025
    Share Share
    Tiefenbacher Group Career Stories No 3
    Tiefenbacher Group Career Stories No 3

    29 Aug 2025

    // PRESS RELEASE

    https://tiefenbacher-pharmaceuticals.com/news/tiefenbacher-group-career-stories-no-3/

    PRESS RELEASE
    29 Aug 2025
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Tiefenbacher Pharmaceuticals Prepares Launch of the Anticoagulant Rivaroxaban

    Details:

    Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.


    Lead Product(s): Rivaroxaban

    Therapeutic Area: Hematology Brand Name: Xarelto-Generic

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 09, 2024

    Tiefenbacher Compnay Banner

    01

    Tiefenbacher Group

    Germany
    arrow
    AOCS Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Lead Product(s) : Rivaroxaban

    Therapeutic Area : Hematology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Tiefenbacher Pharmaceuticals Prepares Launch of the Anticoagulant Rivaroxaban

    Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.

    Product Name : Xarelto-Generic

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    April 09, 2024

    Tiefenbacher Compnay Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Tiefenbacher Pharmaceuticals Successfully Launches the Anticoagulant Rivaroxaban on Day One in Canada

    Details:

    Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.


    Lead Product(s): Rivaroxaban

    Therapeutic Area: Hematology Brand Name: Xarelto-Generic

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable November 16, 2023

    Tiefenbacher Compnay Banner

    02

    Tiefenbacher Group

    Germany
    arrow
    AOCS Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Lead Product(s) : Rivaroxaban

    Therapeutic Area : Hematology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Tiefenbacher Pharmaceuticals Successfully Launches the Anticoagulant Rivaroxaban on Day One in Can...

    Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.

    Product Name : Xarelto-Generic

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    November 16, 2023

    Tiefenbacher Compnay Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Tiefenbacher Pharmaceuticals Successfully Launches the Generic Version of Teriflunomide in more than 20 European Countries

    Details:

    Aubagio-Generic (teriflunomide) is a USFDA approved pyrimidine synthesis inhibitor which is indicated for the treatment of patients with relapsing forms of multiple sclerosis.


    Lead Product(s): Teriflunomide

    Therapeutic Area: Neurology Brand Name: Aubagio-Generic

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 27, 2023

    Tiefenbacher Compnay Banner

    03

    Tiefenbacher Group

    Germany
    arrow
    AOCS Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Lead Product(s) : Teriflunomide

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Tiefenbacher Pharmaceuticals Successfully Launches the Generic Version of Teriflunomide in more th...

    Details : Aubagio-Generic (teriflunomide) is a USFDA approved pyrimidine synthesis inhibitor which is indicated for the treatment of patients with relapsing forms of multiple sclerosis.

    Product Name : Aubagio-Generic

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    September 27, 2023

    Tiefenbacher Compnay Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Tiefenbacher Pharmaceuticals Successfully Launches the Antihistamine Bilastine for A Market Entry as Over-the-counter (OTC) Medicine in Germany

    Details:

    Bilastine Tiefenbacher (Bilastine) is a histamine H1 receptor inverse agonist, small molecule drug candidate which is indicated for the treatment of allergic rhino-conjunctivitis & urticaria.


    Lead Product(s): Bilastine

    Therapeutic Area: Immunology Brand Name: Bilastine Tiefenbacher

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 14, 2023

    Tiefenbacher Compnay Banner

    04

    Tiefenbacher Group

    Germany
    arrow
    AOCS Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Lead Product(s) : Bilastine

    Therapeutic Area : Immunology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Tiefenbacher Pharmaceuticals Successfully Launches the Antihistamine Bilastine for A Market Entry ...

    Details : Bilastine Tiefenbacher (Bilastine) is a histamine H1 receptor inverse agonist, small molecule drug candidate which is indicated for the treatment of allergic rhino-conjunctivitis & urticaria.

    Product Name : Bilastine Tiefenbacher

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    March 14, 2023

    Tiefenbacher Compnay Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Tiefenbacher Pharmaceuticals Successfully Launches Generic Version of The Psoriasis Medication Apremilast in Canada

    Details:

    Otezla-Generic (apremilast) is an inhibitor of phosphodiesterase 4 (PDE4). It is indicated for the treatment of adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, and oral ulcers.


    Lead Product(s): Apremilast

    Therapeutic Area: Dermatology Brand Name: Otezla-Generic

    Study Phase: Approved FDFProduct Type: HPAPI

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 01, 2022

    Tiefenbacher Compnay Banner

    05

    Tiefenbacher Group

    Germany
    arrow
    AOCS Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Lead Product(s) : Apremilast

    Therapeutic Area : Dermatology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Tiefenbacher Pharmaceuticals Successfully Launches Generic Version of The Psoriasis Medication Apr...

    Details : Otezla-Generic (apremilast) is an inhibitor of phosphodiesterase 4 (PDE4). It is indicated for the treatment of adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, and oral ulcers.

    Product Name : Otezla-Generic

    Product Type : HPAPI

    Upfront Cash : Inapplicable

    December 01, 2022

    Tiefenbacher Compnay Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    New Market Launch: Tiefenbacher Pharmaceuticals Successfully Launches Generic Versions of The Prostate Cancer Medicines Abiraterone and Abiraterone/pred...

    Details:

    Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe by our partners.


    Lead Product(s): Abiraterone Acetate,Prednisolone

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable November 17, 2022

    Tiefenbacher Compnay Banner

    06

    Tiefenbacher Group

    Germany
    arrow
    AOCS Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Lead Product(s) : Abiraterone Acetate,Prednisolone

    Therapeutic Area : Oncology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    New Market Launch: Tiefenbacher Pharmaceuticals Successfully Launches Generic Versions of The Pros...

    Details : Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe by our partners.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    November 17, 2022

    Tiefenbacher Compnay Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Tiefenbacher Pharmaceuticals Successfully Launches Generic Version of The Anticoagulant Medicine Apixaban in Canada

    Details:

    Apixaban Tiefenbacher (apixaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.


    Lead Product(s): Apixaban

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Apixaban Tiefenbacher

    Study Phase: Approved FDFProduct Type: HPAPI

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 20, 2022

    Tiefenbacher Compnay Banner

    07

    Tiefenbacher Group

    Germany
    arrow
    AOCS Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Lead Product(s) : Apixaban

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Tiefenbacher Pharmaceuticals Successfully Launches Generic Version of The Anticoagulant Medicine A...

    Details : Apixaban Tiefenbacher (apixaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

    Product Name : Apixaban Tiefenbacher

    Product Type : HPAPI

    Upfront Cash : Inapplicable

    October 20, 2022

    Tiefenbacher Compnay Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Tiefenbacher Pharmaceuticals Successfully Launches Generic Version of The Diabetes Medicine Vildagliptin and Vildagliptin /metformin in Africa

    Details:

    Vildagliptin/Metformin generic version launched in Africa market, the drug ais a diabetes medicine that are used to control the blood glucose (sugar) in adults with type 2 diabetes, by inhibiting DPP-4.


    Lead Product(s): Vildagliptin,Metformin

    Therapeutic Area: Endocrinology Brand Name: Vildagliptin-Metformin-Generic

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 08, 2022

    Tiefenbacher Compnay Banner

    08

    Tiefenbacher Group

    Germany
    arrow
    AOCS Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Lead Product(s) : Vildagliptin,Metformin

    Therapeutic Area : Endocrinology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Tiefenbacher Pharmaceuticals Successfully Launches Generic Version of The Diabetes Medicine Vildag...

    Details : Vildagliptin/Metformin generic version launched in Africa market, the drug ais a diabetes medicine that are used to control the blood glucose (sugar) in adults with type 2 diabetes, by inhibiting DPP-4.

    Product Name : Vildagliptin-Metformin-Generic

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    September 08, 2022

    Tiefenbacher Compnay Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Tiefenbacher Pharmaceuticals Expands the Launch of The Anticoagulant Medicine Rivaroxaban to Central America and Further International Markets

    Details:

    Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.


    Lead Product(s): Rivaroxaban

    Therapeutic Area: Hematology Brand Name: Xarelto-Generic

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable July 15, 2022

    Tiefenbacher Compnay Banner

    09

    Tiefenbacher Group

    Germany
    arrow
    AOCS Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Lead Product(s) : Rivaroxaban

    Therapeutic Area : Hematology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Tiefenbacher Pharmaceuticals Expands the Launch of The Anticoagulant Medicine Rivaroxaban to Centr...

    Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.

    Product Name : Xarelto-Generic

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    July 15, 2022

    Tiefenbacher Compnay Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Tiefenbacher Pharmaceuticals Successfully Launches First Generic Version of The Multiple Sclerosis Medicine Teriflunomide in Canada

    Details:

    Aubagio-Generic (teriflunomide) is a USFDA approved pyrimidine synthesis inhibitor which is indicated for the treatment of patients with relapsing forms of multiple sclerosis.


    Lead Product(s): Teriflunomide

    Therapeutic Area: Neurology Brand Name: Aubagio-Generic

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable June 01, 2022

    Tiefenbacher Compnay Banner

    10

    Tiefenbacher Group

    Germany
    arrow
    AOCS Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Lead Product(s) : Teriflunomide

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Tiefenbacher Pharmaceuticals Successfully Launches First Generic Version of The Multiple Sclerosis...

    Details : Aubagio-Generic (teriflunomide) is a USFDA approved pyrimidine synthesis inhibitor which is indicated for the treatment of patients with relapsing forms of multiple sclerosis.

    Product Name : Aubagio-Generic

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    June 01, 2022

    Tiefenbacher Compnay Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDA Orange Book

    read-more
    read-more

    Europe

    read-more
    read-more

    01

    Brand Name : Sertralin Tiefenbach...

    Germany
    arrow
    AOCS Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Sertraline Hydrochloride

    Alfred E Tiefenbacher GmbH

    Dosage Form : Film Coated Tablet

    Dosage Strength : 50mg

    Packaging :

    Brand Name : Sertralin Tiefenbacher

    Approval Date : 12-12-2003

    Application Number : 2.00E+13

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Tiefenbacher Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Brand Name : Sertralin Tiefenbach...

    Germany
    arrow
    AOCS Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Sertraline Hydrochloride

    Alfred E Tiefenbacher GmbH

    Dosage Form : Film Coated Tablet

    Dosage Strength : 100mg

    Packaging :

    Brand Name : Sertralin Tiefenbacher

    Approval Date : 12-12-2003

    Application Number : 2.00E+13

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Tiefenbacher Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Brand Name : Sertraxea

    Germany
    arrow
    AOCS Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Sertraline Hydrochloride

    Alfred E Tiefenbacher GmbH

    Dosage Form : Film Coated Tablet

    Dosage Strength : 50mg

    Packaging :

    Brand Name : Sertraxea

    Approval Date : 23-03-2007

    Application Number : 2.01E+13

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Tiefenbacher Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Brand Name : Sertraxea

    Germany
    arrow
    AOCS Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Sertraline Hydrochloride

    Alfred E Tiefenbacher GmbH

    Dosage Form : Film Coated Tablet

    Dosage Strength : 100mg

    Packaging :

    Brand Name : Sertraxea

    Approval Date : 23-03-2007

    Application Number : 2.01E+13

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Tiefenbacher Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Brand Name : Tifisertral

    Germany
    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Sertraline Hydrochloride

    Alfred E Tiefenbacher GmbH

    Dosage Form : Film Coated Tablet

    Dosage Strength : 50mg

    Packaging :

    Brand Name : Tifisertral

    Approval Date : 23-03-2007

    Application Number : 2.01E+13

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Tiefenbacher Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Brand Name : Tifisertral

    Germany
    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Sertraline Hydrochloride

    Alfred E Tiefenbacher GmbH

    Dosage Form : Film Coated Tablet

    Dosage Strength : 100mg

    Packaging :

    Brand Name : Tifisertral

    Approval Date : 23-03-2007

    Application Number : 2.01E+13

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Tiefenbacher Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Brand Name : Sertraparma

    Germany
    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Sertraline Hydrochloride

    Alfred E Tiefenbacher GmbH

    Dosage Form : Film Coated Tablet

    Dosage Strength : 50mg

    Packaging :

    Brand Name : Sertraparma

    Approval Date : 23-03-2007

    Application Number : 2.01E+13

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Tiefenbacher Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Brand Name : Sertraparma

    Germany
    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Sertraline Hydrochloride

    Alfred E Tiefenbacher GmbH

    Dosage Form : Film Coated Tablet

    Dosage Strength : 100mg

    Packaging :

    Brand Name : Sertraparma

    Approval Date : 23-03-2007

    Application Number : 2.01E+13

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Tiefenbacher Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Brand Name : N/A

    Germany
    arrow
    AOCS Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Regulatory Info : EU Dossier Readiness-Q...

    Registration Country : Germany

    abiraterone

    Alfred E Tiefenbacher GmbH

    Dosage Form : Tablet

    Dosage Strength : 250MG

    Packaging :

    Brand Name :

    Approval Date :

    Application Number :

    Regulatory Info : EU Dossier Readiness-Q...

    Registration Country : Germany

    Tiefenbacher Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Brand Name : N/A

    Germany
    arrow
    AOCS Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

    Regulatory Info : EU Dossier Readiness-Q...

    Registration Country : Germany

    abiraterone

    Alfred E Tiefenbacher GmbH

    Dosage Form : Tablet

    Dosage Strength : 500MG

    Packaging :

    Brand Name :

    Approval Date :

    Application Number :

    Regulatory Info : EU Dossier Readiness-Q...

    Registration Country : Germany

    Tiefenbacher Compnay Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Inspections and registrations

    Check the inspections & registration from this company
    Tiefenbacher Group

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search